Mission Statement, Vision, & Core Values (2026) of Changzhou Qianhong Biopharma CO.,LTD.

From its founding in 1971 in Changzhou, Jiangsu, Changzhou Qianhong Biopharma Co., Ltd. has scaled into a major biopharmaceutical player producing APIs and finished dosage forms-best known for heparin sodium, enoxaparin sodium and a range of digestive enzymes-while expanding domestic distribution and international exports; the company underscored its commitment to innovation with about RMB 310 million invested in R&D in 2022 (a 24% year‑over‑year increase), operates multiple production facilities, pursues stringent quality and ethical standards, and aligns corporate sustainability with a target of a 30% reduction in carbon emissions by 2025 as it holds a market capitalization of approximately CNY 9.84 billion as of December 2025, all reflecting a mission to deliver high‑quality biopharmaceuticals and a vision to become a first‑class global healthcare enterprise.

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Intro

• Core product portfolio: heparin sodium, enoxaparin sodium (low-molecular-weight heparin), and a range of digestive enzyme formulations.
• R&D emphasis: invested ~RMB 310 million in R&D in 2022, a 24% increase versus 2021, underscoring a strategic shift toward pipeline and process innovation.
• Market positioning: publicly traded (002550.SZ) with a market capitalization of approximately CNY 9.84 billion as of December 2025.
• Global reach: domestic distribution across China combined with exports to international markets, broadening revenue channels and regulatory engagement.

• Develop safe, effective polysaccharide- and protease-based therapeutics that improve patient outcomes.
• Maintain high-quality, compliant manufacturing to ensure global supply reliability.
• Balance commercial performance with scientific rigor and regulatory integrity.

• Become a leading global supplier of specialty anticoagulants and enzyme therapeutics.
• Expand internationally through quality, regulatory approvals, and strategic partnerships.
• Advance transformative R&D to deliver next-generation APIs and formulations.

• Quality first - strict GMP and quality control across API and finished product lines.
• Innovation-driven - sustained R&D investment (RMB 310M in 2022) to fuel pipeline growth.
• Compliance and ethics - adherence to domestic and international regulatory standards.
• Customer and patient focus - reliable supply and clinically meaningful products.
• Sustainability and social responsibility - responsible sourcing and community engagement.

• Scale advanced manufacturing capacity for heparin derivatives and digestive enzymes to meet domestic and export demand.
• Invest R&D resources into process optimization, biosafety, and new indications for protease therapeutics.
• Pursue regulatory approvals and market entry in key overseas territories to diversify revenue streams.
• Strengthen collaborations with research institutions and CROs to accelerate time-to-market.

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Overview

• Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) is dedicated to the development and manufacturing of high-quality biopharmaceutical products, with a mission centered on delivering innovative, safe and effective medicines to patients worldwide.
• The company maintains stringent quality standards across R&D, production and distribution to ensure product safety and clinical efficacy.
• Qianhong emphasizes sustainable growth, balancing commercial expansion with long-term R&D investment and environmental, social and governance (ESG) commitments.
• By focusing on advanced therapeutics and biomanufacturing excellence, the company aims to measurably enhance patient outcomes across multiple therapeutic areas.
• R&D commitment: sustained reinvestment of revenues into discovery, process development and clinical programs to accelerate pipeline maturation and broaden therapeutic reach.

• To become a globally respected biopharmaceutical company recognized for innovation, manufacturing quality and meaningful patient impact.
• To expand a portfolio of advanced biologics and biosimilars that improve accessibility and standards of care regionally and internationally.
• To leverage scalable GMP manufacturing and strategic partnerships to bring high-value biologics from bench to bedside faster and more safely.

• Quality First - uncompromising adherence to GMP, ISO and regulatory best practices across all sites and products.
• Patient Centricity - all programs and operational decisions prioritize measurable patient benefit and safety.
• Scientific Rigor - evidence-driven development and robust data integrity in R&D and clinical activities.
• Integrity and Compliance - transparent reporting, ethical collaborations and regulatory compliance across markets.
• Sustainable Growth - prudent financial management, environmental responsibility and long-term value creation for stakeholders.
• Collaboration - building alliances with academic institutions, CROs and global partners to accelerate innovation and market reach.

• Pipeline enrichment - advancing biologics and biosimilar candidates through preclinical and clinical milestones.
• Manufacturing scale-up - expanding GMP capacity and process optimization to support commercial launches and export demand.
• Quality systems enhancement - continuous improvement programs to reduce deviations, increase yields and ensure regulatory readiness.
• Global market expansion - regulatory filings and partnership models targeted at APAC, EMEA and selected international markets.
• ESG and sustainability - energy efficiency, waste reduction and supply-chain responsibility integrated into operations.

• Qianhong measures success not only by topline growth but by pipeline progression (IND/CTA filings, pivotal trials) and regulatory approvals that deliver new patient therapies.
• Key performance indicators include product quality metrics (yield, purity), time-to-market for lead candidates, regulatory milestones achieved and sustainable margin improvement from biomanufacturing efficiencies.
• The company's capital allocation prioritizes capacity expansion, platform technology upgrades and strategic partnerships to accelerate commercialization.

• Quality systems and continuous improvement programs reduce batch failures and support faster regulatory approvals.
• Patient-focused development plans include real-world evidence initiatives and post-marketing safety surveillance to continually assess therapeutic benefit.
• Strategic collaborations with academic and industrial partners broaden access to specialized technologies and accelerate clinical programs.
• Investment in talent and infrastructure builds long-term capability for complex biologics development and global supply.

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Mission Statement

• Committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.
• Aiming to be a leading international innovative company originating from China, reflecting ambition on the global stage.
• Dedicated to continuous innovation, regulatory excellence, and scalable global commercialization.
• Focused on sustainable growth, expanded therapeutic pipelines, and strategic partnerships that accelerate global market entry.

• Innovation & R&D: Prioritize high-value biologics and specialty small molecules with clear unmet medical needs.
• Quality & Compliance: Adhere to global GMP, clinical and regulatory standards to support international approvals and exports.
• Global Commercialization: Build commercial footprints and partnerships in APAC, EU and select global markets.
• Sustainable Operations: Invest in capacity expansion, digital manufacturing and ESG-aligned practices.

• R&D budget prioritized toward late-stage candidates and lifecycle management of core products.
• Capital expenditure focused on scale-up of biologics capacity and quality systems to meet export demands.
• Commercial spend allocated to market access, regulatory dossiers and selected in-market partnerships.

• Achieve compounded annual revenue growth in the mid-to-high teens through pipeline commercialization and international sales expansion.
• Increase R&D output measured by IND/NDA filings and international regulatory submissions year-over-year.
• Improve gross margin by operational efficiency and higher-mix innovative products.

• Patients: Deliver safe, effective medicines that meet unmet needs.
• Investors: Transparency in reporting and disciplined capital allocation to maximize long-term returns.
• Employees: Foster a culture of scientific excellence, ethical conduct and continuous learning.
• Partners & Regulators: Maintain collaborative, compliant relationships for sustainable global expansion.

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Vision Statement

• Integrity: Uphold transparent regulatory compliance, anti-corruption controls, and rigorous clinical ethics across all operations.
• Innovation: Prioritize breakthrough biologics and improved formulations via sustained R&D investment and strategic collaborations.
• Quality assurance: Maintain and elevate quality management systems to meet international GMP, ISO and pharmacovigilance standards.
• Collaboration: Foster cross-functional teamwork internally and partnerships with CROs, academic institutions and global distributors.
• Customer focus: Align product development and supply-chain responsiveness to patient needs and healthcare-provider requirements.
• Sustainability: Reduce carbon footprint and embed ESG metrics into corporate governance, targeting a 30% reduction in carbon emissions by 2025.

• Integrity: Implemented whistleblower channels, annual third-party compliance audits covering 100% of commercial operations.
• Innovation: Allocated R&D budget to 18 active projects including 6 biologics in preclinical/clinical stages; target to file 4 INDs within 24 months.
• Quality assurance: Rolling investment in quality systems-annual capital spend of RMB 45 million to upgrade cleanrooms and process analytics.
• Collaboration: Strategic partnerships with 5 leading CROs and 3 university labs for translational research and talent pipelines.
• Customer focus: Implemented KPI-driven customer service SLAs and post-market surveillance, achieving 95% on-time delivery rate in domestic hospitals.
• Sustainability: Energy-efficiency upgrades, waste-reduction programs, and supplier-engagement to meet the 30% emissions cut by 2025 milestone.